DE69921981D1 - ZUSAMMENSETZUNG AUS MUTIERTERN PEPTIDEN, DERIVATE DES hsp70 UND IHRE VERWENDUNG IN DER IMMUNTHERAPIE VON KREBS - Google Patents

ZUSAMMENSETZUNG AUS MUTIERTERN PEPTIDEN, DERIVATE DES hsp70 UND IHRE VERWENDUNG IN DER IMMUNTHERAPIE VON KREBS

Info

Publication number
DE69921981D1
DE69921981D1 DE69921981T DE69921981T DE69921981D1 DE 69921981 D1 DE69921981 D1 DE 69921981D1 DE 69921981 T DE69921981 T DE 69921981T DE 69921981 T DE69921981 T DE 69921981T DE 69921981 D1 DE69921981 D1 DE 69921981D1
Authority
DE
Germany
Prior art keywords
mutter
hsp70
immunotherapy
peptides
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69921981T
Other languages
English (en)
Other versions
DE69921981T2 (de
Inventor
Frederic Triebel
Catherine Gaudin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Gustave Roussy (IGR)
Original Assignee
Institut Gustave Roussy (IGR)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Gustave Roussy (IGR) filed Critical Institut Gustave Roussy (IGR)
Application granted granted Critical
Publication of DE69921981D1 publication Critical patent/DE69921981D1/de
Publication of DE69921981T2 publication Critical patent/DE69921981T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69921981T 1998-04-22 1999-04-22 ZUSAMMENSETZUNG AUS MUTIERTERN PEPTIDEN, DERIVATE DES hsp70 UND IHRE VERWENDUNG IN DER IMMUNTHERAPIE VON KREBS Expired - Fee Related DE69921981T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9805033 1998-04-22
FR9805033A FR2777890B1 (fr) 1998-04-22 1998-04-22 Composes peptidiques d'hsp70 utiles dans l'immunotherapie du cancer
PCT/FR1999/000957 WO1999054464A1 (fr) 1998-04-22 1999-04-22 COMPOSES PEPTIDIQUES MUTES, DERIVES DE hsp70, UTILES DANS L'IMMUNOTHERAPIE DU CANCER

Publications (2)

Publication Number Publication Date
DE69921981D1 true DE69921981D1 (de) 2004-12-23
DE69921981T2 DE69921981T2 (de) 2005-04-07

Family

ID=9525534

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69921981T Expired - Fee Related DE69921981T2 (de) 1998-04-22 1999-04-22 ZUSAMMENSETZUNG AUS MUTIERTERN PEPTIDEN, DERIVATE DES hsp70 UND IHRE VERWENDUNG IN DER IMMUNTHERAPIE VON KREBS

Country Status (9)

Country Link
US (1) US6855802B1 (de)
EP (1) EP1073733B1 (de)
JP (1) JP2002512030A (de)
AU (1) AU762903B2 (de)
CA (1) CA2325864A1 (de)
DE (1) DE69921981T2 (de)
ES (1) ES2233035T3 (de)
FR (1) FR2777890B1 (de)
WO (1) WO1999054464A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2393589A1 (en) * 1999-12-07 2001-06-14 Stressgen Biotechnologies Corp. Compositions and methods for detecting stress-inducible proteins
US6964851B2 (en) 1999-12-07 2005-11-15 Stressgen Biotechnologies Corp. Compositions and methods for detecting stress-inducible proteins
JP5610659B2 (ja) * 2000-07-21 2014-10-22 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 多成分生物学的輸送システム
EP1209226A3 (de) * 2000-11-07 2002-06-05 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Reifen von dendritischen Zellen durch die Verwendung von rekombinante Hitzeschock-Protein 70 (hsp70)
US20050267020A1 (en) * 2001-09-27 2005-12-01 Olivier Faure Polypeptides derived from inducible hsp70 and pharmaceutical compositions containing the same
GB0123756D0 (en) * 2001-10-03 2001-11-21 King S College London A novel chaperone-type of adjuvant for vaccination - Basic 1
DE10163130B4 (de) * 2001-12-20 2009-05-14 Cyto Tools Gmbh Apoptotisch wirksame Peptide und diese umfassende pharmazeutische Zusammensetzungen
IL148401A0 (en) * 2002-02-26 2002-09-12 Hadasit Med Res Service Hsp70-derived peptides and uses thereof in the diagnosis and treatment of autoimmune diseases
HUE029919T2 (en) * 2006-02-02 2017-04-28 Massachusetts Gen Hospital Genetically modified antibody stress protein fusions
US8754094B2 (en) * 2007-08-15 2014-06-17 The Research Foundation Of State University Of New York Methods for heat shock protein dependent cancer treatment
EP2044949A1 (de) 2007-10-05 2009-04-08 Immutep Verwendung von rekombinantem LAG-3 oder Derivaten daraus zur Auslösung einer Monozyten-Immunreaktion
PL2659904T3 (pl) 2008-06-26 2016-01-29 Orphazyme Aps Zastosowanie Hsp70 jako regulatora aktywności enzymatycznej
RU2586774C2 (ru) 2010-08-27 2016-06-10 Пантархей Байосайенс Б.В. Иммунотерапевтический способ лечения рака простаты
PL2646044T3 (pl) 2010-11-30 2020-03-31 Orphazyme A/S Sposoby zwiększenia aktywności wewnątrzkomórkowej Hsp70
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
EP3922242A1 (de) 2014-09-15 2021-12-15 Orphazyme A/S Arimoclomolformulierung
WO2016080830A2 (en) 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
EP3782624A1 (de) 2016-04-29 2021-02-24 Orphazyme A/S Arimoclomol zur behandlung mit glucocerebrosidase assoziierten störungen
EP3703734A1 (de) 2017-10-31 2020-09-09 Pantarhei Bioscience B.V. Immuntherapeutische verfahren zur behandlung und/oder vorbeugung von lungenkrebs
US20210317165A1 (en) 2018-09-03 2021-10-14 Laboratoire Hra-Pharma Zp3 fragments in immunotherapy of ovarian cancer
EP4247792A1 (de) 2020-11-19 2023-09-27 Zevra Denmark A/S Verfahren zur herstellung von arimoclomolcitrat und zwischenprodukten davon
EP4419122A1 (de) 2021-10-19 2024-08-28 Sciencemed Spólka Z Ograniczona Odpowiedzialnoscia Männliche kontrazeption

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990002564A1 (en) * 1988-09-12 1990-03-22 Codon Vaccine diagnostic employing proteins homologous to heat shock proteins of trypanosoma cruzi

Also Published As

Publication number Publication date
DE69921981T2 (de) 2005-04-07
AU3425899A (en) 1999-11-08
EP1073733A1 (de) 2001-02-07
FR2777890B1 (fr) 2000-12-29
US6855802B1 (en) 2005-02-15
ES2233035T3 (es) 2005-06-01
AU762903B2 (en) 2003-07-10
EP1073733B1 (de) 2004-11-17
JP2002512030A (ja) 2002-04-23
CA2325864A1 (fr) 1999-10-28
WO1999054464A1 (fr) 1999-10-28
FR2777890A1 (fr) 1999-10-29

Similar Documents

Publication Publication Date Title
DE69921981D1 (de) ZUSAMMENSETZUNG AUS MUTIERTERN PEPTIDEN, DERIVATE DES hsp70 UND IHRE VERWENDUNG IN DER IMMUNTHERAPIE VON KREBS
ATE514676T1 (de) Ionisierbare indolinon derivate und deren verwendung als ptk liganden
ATE217862T1 (de) Aminophenolderivate und ihre verwendung in der kosmetik
DE60017894D1 (de) Diaminothiazole und ihre verwendung zur inhibierung von proteinkinasen
DE69732871D1 (de) Basisches Protein Zusammensetzung, basisches Peptid Zusammensetzung und deren Verwendung
DE60025147D1 (de) Kosmetische Zusammensetzung und Verwendungen
DE59812907D1 (de) Substituierte Isochinolin-3-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
ATE344246T1 (de) Heteroaryl aminoguanidin- und alkoxyguanidinderivate und ihre verwendung als proteasehemmer
DE69720389D1 (de) Zementzusammensetzungen und ihre Verwendung
DE60016326D1 (de) Wasser-absorbierende Zusammensetzung und ihre Verwendung
DE60040947D1 (de) Pulverlackzusammensetzung und Vernetzungsmittelzusammensetzung
DE69823804D1 (de) Azeotrope methoxyperfluorpropanzusammensetzungen und deren verwendung
EP1068217A4 (de) Neuartige moleküle der card-verwandten proteinfamilie und anwendungen derselben
DE59804276D1 (de) Substituierte Aminoverbindungen und ihre Verwendung als analgetisch wirksame Substanzen
DE60003389D1 (de) Monolithische zusammensetzung enthaltend feste partikeln und bindemittel
DE69833788D1 (de) Kompositmaterial und dessen verwendung
NO20015516L (no) Preparater og anvendelser av ET743 for behandling av kreft
DE60022828D1 (de) Kosmetikeinheit und deren Zusammensetzung
DE69815096D1 (de) Selbst aggregierende protein zusammensetzungen und ihre verwendung als dichtungsmassen
DE60109397D1 (de) Alkyl-substituierte Derivate von 4,5,6,7-Tetrahydro-4-indan und deren Verwendung in Parfümzubereitungen
ATE250339T1 (de) Dormanz-brechende zusammenstezung und deren verwendung
ATE270272T1 (de) C11-oxymyl- and hydroxylamino-prostaglandine und ihre anwendung als arzneimittel
ATE260258T1 (de) Substituierte isochinoline derivate und ihre verwendung als anticonvulsiva
DE69812256D1 (de) 7-propyl-benzodiosepin-3-one und dessen Verwendung in Parfümerie
DE60017924D1 (de) Rekombinante, adenovirale vektoren und ihre verwendung zur behandlung von leberzirrhose

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee